Special Issue

A New Development in Medicine: Tear Biomarkers and Non-invasive Disease Testing

Message from the Guest Editors

In the realm of modern medicine, we stand at the threshold of an exciting era, one where the unassuming tear fluid harbors remarkable potential as a wellspring of biomarkers. This potential extends far beyond ophthalmology, encompassing a spectrum of diseases, ranging from neurological conditions to diabetes to cancer and mental health disorders. Tear biomarkers, characterized by their non-invasive nature and ease of collection, offer a transformative approach to early disease detection and monitoring. We eagerly anticipate submissions that illuminate the current state of the art in this promising domain, particularly those that address the following key inquiries: 1) Which tear biomarkers exhibit the most promise in early disease diagnosis? 2) How can tear biomarkers be harnessed for proactive disease screening among at-risk populations? 3) In what ways can tear biomarkers facilitate ongoing disease progression monitoring and treatment efficacy assessments? 4) How might tear biomarkers drive the development of novel diagnostic tests and therapeutic interventions?

Guest Editors

Dr. Kunhong Xiao

Center for Proteomics & Artificial Intelligence, Center for Clinical Mass Spectrometry, Cancer Institute, Allegheny Health Network, 100 S Jackson Ave., Pittsburgh, PA 15202, USA

Dr. Leanne Labriola

1. Southwest Pennsylvania Eye Center, Washington, PA 15301, USA
2. Sewickley Eye Group, Sewickley, PA 15143, USA

Deadline for manuscript submissions

closed (30 September 2024)

MDPI

Biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).